Overview
Epstein-Barr virus (EBV) is a common infection that can lead to mononucleosis, which may cause severe symptoms in adolescents and young adults. It also poses significant risks for those with compromised immune systems.
Traditionally, the monospot test is used as a first step in EBV testing. However, additional EBV serology testing is often necessary to accurately determine the stage of infection, guide treatment, and improve diagnostic accuracy. This typically requires up to five additional EBV IgM and IgG serology tests, which can complicate workflows and extend result turnaround time. Fortunately, there’s an easier way.
The Power of Multiplex EBV Testing
The BioPlex 2200 EBV IgM and BioPlex 2200 EBV IgG panels detect and differentiate five distinct EBV IgM and IgG antibodies.
EBV IgM
- Heterophile IgM
- EBV VCA IgM
EBV IgG
- EBV VCA IgG
- EBV EA-D IgG
- EBV NA-1 IgG
With multiplexed EBV results, laboratories can easily generate a complete serological profile, allowing physicians to identify the stage of infection and initiate appropriate treatments quickly.
“…Because of the better sensitivity observed, we further recommend testing all five antibodies when trying to diagnose primary acute EBV disease.”
Klutts J et al. (2009)1
Streamline EBV Testing
Discover how the BioPlex 2200 EBV IgM and BioPlex 2200 EBV IgG panels transform EBV testing and workflow.
See How Multiplex Results Simplify Testing
Test Smarter, Not Harder
With the power of multiplex technology, the BioPlex 2200 EBV IgM and EBV IgG panels can generate up to five distinct EBV results with only two tests, enabling physicians to more efficiently characterize the stage of EBV infection.
Maximize Efficiency, Minimize Effort
Traditional EBV testing requires manual test methods and numerous manual processing steps. With the fully automated BioPlex 2200 System, your technologists can complete EBV testing workloads with less hands-on time. Simply load the samples and walk away.
Test Consolidation: The Power of Simplicity
The BioPlex 2200 EBV panels are part of an extensive test menu for the BioPlex 2200 System, allowing your lab to consolidate more than 50 infectious disease and autoimmune tests onto one high-throughput, fully automated analyzer. This streamlines workflow, simplifies testing, and enhances efficiency.
Improve Patient Care
Patient care is at the heart of what you do. From faster turnaround times to high-quality, clinically relevant results, we’ll help you help your patients.
Identify Acute EBV More Reliably
Immunocompromised patients, such as transplant recipients and those undergoing chemotherapy, are at increased risk for severe complications when contracting acute EBV.* That means rapid identification is crucial.
Traditional methods like the monospot test may have low sensitivity for early infection and fail to distinguish EBV from similar illnesses.2 In contrast, a single multiplex test that detects both EBV VCA IgM and Heterophile offers improved sensitivity and reduces the risk of misclassifying acute EBV infections.
Faster Result Turnaround Time
The BioPlex 2200 EBV IgM and EBV IgG panels use multiplex technology to provide multiple results per test. This can accelerate EBV result turnaround time, enabling faster diagnoses and improving patient outcomes.
Comprehensive Characterization of EBV
Fully characterizing an EBV infection enables physicians to more accurately assess its stage. A comprehensive serological profile distinguishes acute, past, and reactivated EBV infections, guiding physicians on appropriate treatments or the need for further testing.
| Antibody | Clinical Onset Phase | Persistence | Indication |
|---|---|---|---|
| EBV VCA IgM | Early/Acute | Diminishes within 4–6 weeks | Acute infection |
| Heterophile IgM | Early/Acute | Diminishes within 4–6 weeks | Non-specific but associated with acute infection |
| EBV VCA IgG | Acute/Latent | Persists for life | Current or past infection |
| EBV EA-D IgG | Acute/Reactivation | Diminishes in 3–6 months; may persist in 20% of individuals |
Active or reactivated infection |
| EBV NA–1 IgG | Latent, 2–4 months after onset | Persists for life | Past infection |
Confidence in EVERY Patient Result
In addition to external independent quality controls, patented quality control beads are integrated into the BioPlex 2200 EBV IgM and EBV IgG panels. This enables the real-time analysis of assay parameters for every test, providing additional confidence in every patient result.
Minimize Costs
To identify acute and latent infections, EBV testing requires multiple labor-intensive and costly tests. The BioPlex 2200 EBV IgM and EBV IgG panels can help your lab optimize testing processes and minimize costs.
Test Processing Costs
Replacing 5 individual EBV IgM and EBV IgG serology tests with only 1 EBV IgM and 1 EBV IgG test means fewer costly tests, fewer costly calibrations, fewer costly quality control runs, and fewer costly reagents and consumable supplies.
Labor/Staffing Costs
Multiplexing generates multiple individual results per test, helping to lighten staff workloads, reduce hands-on time, and free technicians to focus on other value-added activities.
Send-Out Testing Costs
Performing EBV testing in-house helps minimize expenses and costly operational inefficiencies associated with send-out testing.
Case Study: Monthly Labor Time Comparison Table
See how you can reduce labor costs and better utilize the expertise of your medical laboratory technologists, your lab’s most valuable asset.
This case study compares the manual processing times required to perform EBV testing on the BioPlex 2200 System and on a competitor’s fully automated system.
In total, 34% less hands-on time was required with multiplexed EBV testing than with the competing tests.
For a personalized workflow analysis of your lab, please contact your Bio-Rad representatives.
Complementary Products
VIROTROL EBV Quality Control
The VIROTROL EBV quality control is an unassayed quality control for use with assays detecting IgG and IgM antibodies to the viral capsid antigens and IgG antibodies to the nuclear antigens of the Epstein-Barr virus.
VIROCLEAR EBV Quality Control
The VIROCLEAR EBV quality control is an unassayed, non-reactive quality control for use with assays detecting IgG and IgM antibodies to viral capsid antigens, IgG antibodies to early antigens, and IgG antibodies to viral nuclear antigens of the Epstein-Barr virus.
Notes
- * Results obtained from immunocompromised individuals and neonates should be interpreted with caution. Please refer to the IFU.
References
- 1. Klutts J et al. (2009). Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. Journal of Clinical Microbiology 47, 3204–3210.
- 2. Centers for Disease Control and Prevention (2024). Laboratory Testing for Epstein-Barr Virus (EBV). https://www.cdc.gov/epstein-barr/php/laboratories/index.html, accessed February 24, 2025.
These pages list our product offerings in these areas. Some products have limited regional availability. If you have a specific question about products available in your area, please contact your local sales office or representative.
Ordering
items
Use the filters below to refine results!
